News and Trends 22 Jun 2022
Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding
Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […]